Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.
Catalent and Zumutor Biologics have combined their technologies to create antibodies with enhanced Antibody Dependent Cellular Cytotoxicity (ADCC) without compromising production levels.
Abzena will make Faron's drug candidate Clevegen - an antibody that neutralises a subset of immune cells linked to tumor proliferation - at a recently acquired single-use facility in California.
Scancell Holdings has stopped dosing in a long-term extension arm of a trial of its cancer vaccine SCIB1 after discovering the product is no longer within original specification.
Octapharma has withdrawn one lot of its immune deficiency treatment Octagam after receiving reports of reports of allergic skin reactions in patients treated with the product.
Heptares Therapeutics and Kymab Limited have entered into a strategic collaboration to discover, develop, and commercialize novel antibody therapeutics.
Crown Bioscience has developed humanized mouse cancer models which it claims provide biologic drug developers with an improved means of assessing efficacy.
New facilities and a successful CMO tech transfer have helped turnaround the manufacturing of cell therapy product Ovasave, says TxCell after production was suspended last year.
Mucosis has been awarded a Wellcome Trust grant of €3.7m ($4m) to help develop a Respiratory Syncytial Virus (RSV) vaccine using its intranasal delivery platform.
Pfizer and Bioatla have licensed each other’s technology platforms to develop ADCs with Conditionally Active Biologic (CAB) antibodies as the payload delivery vehicles.
Making the newly approved asthma drug Nucala (mepolizumab) involves facilities on both sides of the Atlantic according to GSK, which says it has no plan to outsource production.
A successful HIV vaccine will have to induce several broadly neutralising antibodies to mimic some patients’ immune response to HIV infection, according to the Duke Human Vaccine Institute.
Development of a successful HIV vaccine will rely on broadly neutralising antibodies (bNAbs), says the Director of the National Institute of Allergy and Infectious Diseases.
Catalent has licensed an expression technology from Excelimmune it says could offer biologics makers a cost-effective and simple way to make antibody combination therapies.
Mice engineered to recognise light-emitting markers as self will let cancer drug developers to track tumor growth in animals with functioning immune systems say US researchers.
Green Cross Biotherapeutics has begun constructing a facility in Canada it says will produce up to five tons of injectable antibodies and 25,000kg of albumin annually.
Intertek will open an immunochemistry lab in Manchester, UK to cater for growing demand for specialised analytical services from biologics and biosimilars developers.
AstraZeneca has inked a development and commercialisation deal with Celgene for its haematology programmed cell death ligand 1 (PD-L1) candidate, MEDI4736.
A doctor whose thumb was punctured by a needle while working with Ebola patients in Sierra Leone received Merck & Co.’s vaccine candidate and did not develop the virus.
Abenza subsidiary Antitope has extended its relationship and will provide manufacturing cell lines for two developing HIV vaccines from the French National Institute of Health and Medical Research (INSERM); the National Health Agency for Research on AIDS...
The Scripps Research Institute has created a nicotine conjugate vaccine with a technique it says could also treat cocaine, heroin, and methamphetamine addiction.
In an exclusive extract from her recent book On Immunity: An Innoculation, author Eula Biss describes her exploration of the social history and cultural myths surrounding vaccines.To be in with a chance of winning a copy, enter BioPharma-Reporter.com's...
The $20m funding led by Pfizer Venture Investments will help advance a platform to make Probodies which CytomX says offers more precise tumour targeting than antibodies.
Sotio has selected local CRO Accord Research to carry out Phase I/II trials on its dendritic cell vaccines to treat patients with lung cancer in the Czech Republic.
Korean and Harvard University scientists have developed a way to non–surgically inject programmable biomaterial to deliver a 3D vaccine that can more effectively treat diseases like cancer or HIV.
Pierre Fabre has spared its biopharmaceutical research team from job cuts unveiled last night, signalling that high value biologics will be a focus for its reduced pharma R&D activities.
Manufacturers developing Ebola vaccines will be immune from lawsuits following a decision by US HHS (Health and Human Services) to issue a declaration on the matter.
An API facility in Singapore acquired by AbbVie on the site where it is building a $320m biologics plant will support the firm's antibody-drug conjugate (ADC) pipeline.
With the goal of developing a thermostable tuberculosis vaccine, IDRI (Infectious Disease Research Institute) was awarded a contract from the NIH’s National Institute of Allergy and Infectious Diseases that could be worth up to $11.9m.
UK researchers working with GSK say a newly identified immune cell communication mechanism could explain why some drugs don’t work and drive development of smaller, large molecule meds.
Lack of funding is threatening development of a nasal spray vaccine shown to provide long-term protection for non-human primates against the Ebola virus, the lead researcher told this publication in an exclusive interview.
Personalized immunotherapy developer Argos Therapeutics has broken ground on a new 100,000 square-foot biomanufacturing facility in Durham, North Carolina.
